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ABSTRACT: The glucocorticoid receptor (GR) is a ligand-binding dependent
transcription factor that ultimately regulates vital biological processes and inflammation
response through specific gene expression control, thus representing a notable drug target
to explore. Structurally, its ligand binding domain (LBD) harbors the region for the
ligand-dependent transcriptional activation function 2 (AF-2), a majorly hydrophobic
groove formed by residues from helices H3, H4, and H12, where the H12 position plays a
critical role in AF-2 spatial conformation and GR function as a whole. However, the exact
mechanisms underlying how regulatory ligands control the H12 structure and dynamics
are yet to be elucidated. In this work, we have explored the correlation between ligand
identity and GR LBD H12 behavior through different molecular dynamics (MD)
simulations. After building diverse GR LBD systems in agonist and nonagonist states, we
studied each system’s response in the absence or the presence of an agonist ligand (dexamethasone) or an antagonist ligand
(RU486) using classical MD simulations. We complemented them with steered MD for assessing the transition between those
states and with the Umbrella Sampling method for free-energy evaluation. On the one hand, successfully obtaining fully folded
nonagonist GR LBD states from the partially unfolded crystal GR LBD/RU486 underlines the role of the H1 in the GR LBD
folding pathway. On the other hand, our results describe the H12 as a dynamic ensemble of conformations whose relative
population is in the end determined by the interacting ligand: while dexamethasone privileges only a few poses (determined by
a potential energy surface with a deep minimum), RU486 favors a wider H12 conformational amplitude, as indicated by a flatter
potential landscape. By characterizing the H12 conformation in different conditions, we provide novel GR LBD models that
represent potential targets for rational glucocorticoid drugs design, with the aim of accurately modulating GR activity.
1. INTRODUCTION
Growth, apoptosis, developmental behavior, and metabolism
are among the biological features regulated by a group of
steroid hormones named glucocorticoids (GCs).1,2 Given their
powerful anti-inflammatory and immunosuppressive activities,
they are administered as a treatment for asthma, dermatitis,
rheumatoid arthritis, and other pathologies of autoimmune
origin, while their proapoptotic nature extends GCs application
to hematological neoplasms including various types of
leukemias, lymphomas, and myelomas.3,4 This entitles GCs
to be one of the most frequently prescribed medications
worldwide. However, despite their evident benefits, GCs’
clinical use is often limited by their severe long-term use side
effects, e.g., osteoporosis, diabetes, hypertension, and obesity.
Hence, developing new steroids that can dissociate therapeutic
effects from adverse effects appears both promising and
challenging, since it demands unraveling the molecular
mechanisms underlying GCs physiological and pharmacolog-
ical actions.5
The glucocorticoid receptor (GR) is a transcription factor
classified within the nuclear receptor (NR) superfamily6 and
depicted as a modular protein with three prominent and
conserved domains: an N-terminal transactivation domain, a
central DNA-binding domain (DBD), and a C-terminal ligand-
binding domain (LBD). The N-terminal domain contains the
AF-1 transcriptional activation domain required for transcrip-
tional enhancement and association with basal transcription
factors. The DBD is composed of two zinc finger motifs which
play a critical role in receptor homodimerization and DNA
binding. The LBD consists of 11 α-helices (H1; H3−H12) and
four small β-strands folding into a globular structure, often
described as a net, enclosing a central hydrophobic ligand-
binding pocket7 (LBP, Figure 1). Besides, LBD also harbors a
second dimerization interface and the domain for the ligand-
dependent transcriptional activation function 2 (AF-2).
Particularly, the AF-2 domain is a majorly hydrophobic groove
formed by residues from helices H3, H4, and H12, where the
H12 position plays a critical role in the AF-2 spatial
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conformation and GR function. Indeed, the AF-2 domain
interacts with specific nonpolar residues present in particular
coregulators’ amino acid motifs (LxxLL and I/LxxII for
coactivators and corepressors families respectively, where x is
any amino acid) arranged on one side of their amphipathic
helix (Figure 1).7
Hitherto, a central issue within the study of NRs is how
regulatory ligands control the structure and dynamics of the
H12.8,9 Initially, the analysis of the first crystallographic
structures of isolated LBD led to propose the so-called
induced-fit hypothesis−also known as the mouse-trap mech-
anism−to explain the molecular basis of action. This
hypothesis postulates that, upon ligand binding, an inactive
state of the receptor suffers a conformational change toward an
agonist state. In the absence of a ligand (apo state), the H12 of
several LBDs was described as a stable helix located away from
the LBD body.10 However, further studies revealed that the
H12 of apo-LBDs cannot be detached from the LBD surface
and concluded that those observed positions were probably a
consequence of artificial crystal packing interactions.11 Thus, in
contrast to the induced-fit hypothesis, the conformational
selection mechanism12 proposes that the receptor’s apo state
comprises an ensemble of conformations in which the H12
swings along different well-folded positions, and where ligand-
binding drives the relative population of each subensemble. In
this sense, by using fluorine-19 (19F) nuclear magnetic
resonance (NMR), Chrisman et al.13 recently proved that
the H12 of the nuclear receptor peroxisome proliferator-
activated receptor gamma (PPARγ) consists of a dynamic
ensemble of conformations where the relative populations of
subensembles correlate with the receptor’s activity. Its AF-2
domain, including the H12, exchanges relatively fast between
many conformations for the apo-receptor. In turn, agonist and
inverse-agonist binding consolidates the complex’s ensemble
into structurally distinct active or inactive states, which favors
coactivator or corepressor binding, respectively.
For the GR LBD, more than 40 crystallographic structures
are archived in the Protein Data Bank (PDB, www.rcsb.org),
mostly bound to ligands that stabilize the H12 in an agonist
conformation.14 For nonagonist states, two structures of
RU486 (Figure 1) complexes were resolved,15,16 providing
information on the antagonistic mode of action of this
antiglucocorticoid. In pdb:1nhz, the dimethylaniline group of
RU486 appears to be preventing the H12 from adopting an
agonistic conformation. However, this structure is incomplete
and shows a fully deployed H12 bound to another GR LBD
subunit. As described above, this is attributable to a
crystallization technique’s artifice. In turn, the case of
pdb:3h52 tetrameric structure is more informative: the
receptor is observed with the H12 in three different positions
(all consistent with nonagonist states) where some allow the
union of a peptide corresponding to a corepressor motif.
Unfortunately, lacking residues at the H11−H12 region and an
incomplete folding of the H1 and H1−H3 loop in the four
monomers of pdb:3h52 prevent its direct use for further
molecular modeling studies.
During the last decades, computational modeling techniques
have enriched the study of proteins and constitute a profitable
tool that complements and expands experimental data.17,18 A
prominent example is the case of molecular dynamics (MD)
simulation that can render protein’s overall behavior in
solution, thus allowing the study of protein inherent flexibility.
Nevertheless, its robustness is limited in the presence of large
energetic barriers between possible relevant conformations. To
overcome this weakness, enhanced sampling methods have
been developed, which expand and improve the understanding
of the potential energy surface of a given system.19 In the case
of NRs, MD simulation allowed for obtaining valuable
Figure 1. Left panel: three-dimensional structure of the GR LBD (pdb:1m2z, chain A) showing the H3, H4, and H12 helices forming the AF-2
domain which interacts with the NCoA2 peptide (in green). The position of the ligand binding pocket (LBP) is indicated as a cyan surface. A
schematic of the secondary structure is shown below (numbers indicate first and final residues of each helix). Right panel: 2D and 3D structures of
the glucocorticoid dexamethasone (dex) and the antiglucocorticoid mifepristone (RU486). The dimethylaniline moiety of RU486 is highlighted.
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information regarding the ligand binding mode, the binding
and unbinding pathways, and their molecular basis of action.20
Moreover, research on the dynamic association between the
H12 position and the action of ligands bound to the LBP was
recently conducted for other steroid receptors: progesterone,21
androgen,22,23 and estrogen24 receptors. However, to our
knowledge, no studies were dedicated to thoroughly analyzing
the conformational equilibria of the H12 in the GR LBD.
The above concerns encouraged us to explore through
different MD simulation methods the correlation between
ligand identity and the GR LBD H12 behavior. With this
purpose, we constructed and studied several systems. The
absence or the presence of an agonist ligand (dexamethasone)
or an antagonist ligand (RU486) was combined with GR LBD
both in agonist and nonagonist states. We envisaged that
dissimilar starting conformations for the classical MD (cMD)
analysis could offer a wider panorama on the H12 dynamics,
while including a combination of steered MD (SMD) and the
Umbrella Sampling (US) method would provide additional
insights into the molecular determinants involved in the
transition between those states.
2. RESULTS
2.1. Construction of GR LBDs in Nonagonist States.
The first aim of this work focused on the in silico construction
of GR LBDs in nonagonist states, to obtain viable structures
for MD simulation studies. As previously mentioned,
monomers from pdb:3h52 have several remarkable H12
conformations, but inconveniently, their N-terminal end (H1
and H1−H3 loop) is unfolded from the LBD body and
packaged in other monomers of the unit cell (Table 1 and
Figure 2a). Although at first sight this phenomenon was
associated with a crystallization artifice,16 a recent study by
Suren et al.25 using single-molecule force spectroscopy showed
Table 1. Summary of the Initial GR LBD Crystal Structures Used for cMD
PDB ID/chain H1 and H1−H3 loop missing residues peptide coregulator receptor state
1m2z/A folded NCoA2 GR LBDAg
3h52/A unfolded 762−767 (H12 C-terminal loop) NCoR1 GR LBDAnt1
3h52/B unfolded NCoR1 GR LBDAnt2
3h52/C unfolded 738−754 (part of H11; H11−H12 loop; part of H12) GR LBDAnt3
3h52/D unfolded 742−750 (H11−H12 loop) and 762−765 (H12) GR LBDAnt1
Figure 2. a) Overall view of the GR LBD/RU486 tetramer (pdb:3h52): chain A in blue, B in green, C in magenta, and D in orange. H1 helices are
schematized as cylinders, and NCoR1 peptides are shown in white. b) Superposition of chain A of pdb:1m2z (red) and chain B of pdb:3h52
(green). c) Absolute value of the difference between the Phi and Psi angles of the H1 and H1−H3 loop segment in pdb:1m2z (chain A) and
pdb:3h52 (chain B). d) Contact map between residues from the H1 and H1−H3 loop and the remainder residues of the receptor for the
equilibrated complexes. e) Main contacts between the H1 and H1−H3 loop and the remainder of the receptor. Cα of the involved residues are
shown as spheres.
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that the H1 folding, in fact, comprises the last step in the
overall folding process and occurs only upon ligand binding.
Thus, monomers of pdb:3h52 structure could presumably
correspond to the open state described by these authors,
constituting an intermediate state receptive to ligand binding.
On this basis, we considered it feasible to obtain completely
folded states of nonagonist systems starting from pdb:3h52
structures.
The structural alignment between pdb:1m2z and pdb:3h52
reveals a large congruence among most GR LBD helices
(Figure 2b). Indeed, their conformation concords from residue
555 (H3) onward, except only for the H11−H12 region where
the helices exhibit slightly different positions (see below). After
comparing H1 and H1−H3 loop backbone dihedral angles Phi
and Psi between the fully folded and the partially unfolded
structures, it was noticed that only three angles at the end of
the H1−H3 loop (PhiAsp554, PsiAsp554, and PhiSer555)
diverged (Figure 2c). Apart from the pointed differences, no
major changes were found along the rest of the loop or helices
H1 and H3. Thus, after having established the structural
similarity between both complexes, we obtained fully folded
nonagonist state systems by replacing the coordinates of
residues 528 to 554 in pdb:3h52 chains with those from the
corresponding residues of chain A in the pdb:1m2z structure.
Each monomer from pdb:3h52 was then analyzed separately.
In chain A (termed here as GR LBDAnt1), there were 6 missing
residues following the H12 C-terminal loop (Table 1), which
we added using the Modeller software. In chain B (termed here
as GR LBDAnt2), the GR LBD was fully resolved. The structural
alignment between both nonagonist GR LBD states here
constructed (GR LBDAnt1 and GR LBDAnt2) and the agonist
system (GR LBDAg) displays differences in the H12 position
(Figure 3a). On the other hand, chain C (termed here as GR
LBDAnt3) revealed a noteworthy H12 position displaced to the
opposite side of the RU486 11β-substituent compared with the
GR LBDAnt1 and GR LBDAnt2, partially occupying the AF-2
groove (Figure 3b). Unfortunately, this helix was poorly
resolved, with as much as 17 residues missing along the H11
C-terminal end, the H11−H12 loop, and part of H12. We
fruitlessly attempted to model this large portion of the receptor
with Modeller, but no convincing structures were achieved.
Lastly, chain D, with 13 unresolved residues along the H11−
H12 loop and H12, showed a H12 configuration equivalent to
the observed in chain A (GR LBDAnt1). Preliminary MD
simulations from these two models showed a high structural
instability, thus, in view of the above, neither chain C nor D
was further considered in this study.
2.2. Initial Evaluation of Nonagonist GR LBDs. GR
LBDAnt1/RU486 and GR LBDAnt2/RU486 complexes were
energetically minimized and equilibrated through classical MD
simulations. The Ramachandran plots of the resulting
structures show that nearly all residues are present in the
favored regions, few are present in the permitted ones, and
only one is present in a forbidden region (Figure S1). Besides,
the secondary structure of the modified section remaining
comparable to that of GR LBDAg, the H1 rearrangement was
notably stabilized in the designated position, and the H1−H3
loop did not suffer substantial structural deformations.
Moreover, the analysis of the contacts between the N-terminal
end and the remainder of the receptor revealed a high
similarity between the original GR LBDAg and the constructed
GR LBDAnt1 and GR LBDAnt2 systems (Figure 2d and e).
Finally, a proper H12 helical conformation was also conserved
(see below).
2.3. Classical Molecular Dynamics Simulation of GR
LBD Systems. Once the quality of the initial GR LBD models
was evaluated, we simulated the systems GR LBDAg, GR
LBDAnt1, and GR LBDAnt2 through 500 ns cMD to study the
dynamic behavior under different conditions (Table 2), i.e., in
the presence of the corresponding ligand (dex for GR LBDAg;
RU486 for GR LBDAnt1 and GR LBDAnt2), in the absence of a
ligand (apo systems), and in the presence of the opposite
ligand (RU486 for GR LBDAg; dex for GR LBDAnt1 and GR
LBDAnt2).
2.3.1. Stability and Fluctuation Pattern of cMD
Trajectories. The stability of cMD trajectories was then
assessed by monitoring backbone atoms’ RMSD relative to the
initial structures. It was noticed that while during the first 200
ns the protein structure evidenced fluctuations, all GR LBDAg
and GR LBDAnt2 systems were stabilized thereafter in constant
values, which were less than 2.2 Å (Figure 4a). In turn, the GR
LBDAnt1 systems suffered significant deviations all along the
simulation, and only for the GR LBDAnt1/RU486 the trajectory
seemed to converge. On the other hand, the RMSD of the H12
Cα atoms (Figure 4b) showed that from 200 ns onward the
H12 position was stabilized in all systems, except for GR
LBDAnt1/apo. Specifically, in systems GR LBDAg and GR
LBDAnt1, the stabilized H12 was located close to the departing
position when their original ligands were involved (dex and
RU486, respectively). For GR LBDAg, the introduction of
RU486 slightly deviated the H12, while the removal of the
Figure 3. a) Superposition of the initial structures of GR LBDAg, GR
LBDAnt1, and GR LBDAnt2 evidencing H12 different positions. b)
Superposition of chain B (GR LBDAnt2) and chain C (GR LBDAnt3) of
pdb:3h52. RU486 is colored in cyan. In both figures, the H11, the
H12, and the H11−H12 loop are highlighted, and the position of the
AF2 groove is indicated with a yellow ellipse.
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ligand considerably deflected it. Likewise, in GR LBDAnt1, the
absence of a ligand provoked a remarkable distortion of the
H12 position.
The RMSF calculated over the last 300 ns from the
simulation (Figure S2) revealed, besides loops’ inherent
mobility, some regions of secondary structure with meaningful
differences among systems. Regarding the C-terminal end, the
GR LBDAg/dex complex showed the least mobility, and the
ligand’s substitution by RU486 clearly increased the fluctuation
of the H11−H12 loop and the H12 first residues. A different
RMSF profile was observed for the GR LBDAnt1 systems, with a
large mobility in the C-terminal end of the H12. Among them,
the GR LBDAnt1/RU486 appeared the most rigid; GR
LBDAnt1/apo presented an increment in H12 mobility, and
GR LBDAnt1/dex had the H11−H12 loop fluctuation
augmented. In turn, the RMSF pattern of GR LBDAnt2
complexes resembled those of the GR LBDAg systems, with
some increased fluctuation for the GR LBDAnt2/dex H12
residues.
2.3.2. Evolution of the H12 Conformation in the cMD
Trajectories. A detailed RSMF global analysis highlighted the
great stability of helices H3 and H10−H11 along the cMD,
particularly of the H3 C-terminal end (residues 568 to 579;
hereinafter, portion “B” or H3B) and the H10−H11 N-
terminal residues 711 to 721 (hereinafter, H10). This
peculiarity allowed us to select these virtually invariant
segments as a spatial reference to analyze the mobility of the
H12 over time. Three vectors of equal direction than segments
H3B, H10, and helix H12 were defined, and the resulting
angles were calculated along the complete cMD. In accordance
with the cited RMSD analysis, the temporal evolution of these
angles evidenced that all systems converged after the 200 ns
(Figure S3) with the exception of GR LBDAnt1/ apo that
presented great instability at the H3B−H12 angle.
For visualization purposes, the last 300 ns of each cMD
trajectory were then examined using box plots (Figure 5). As
expected, the H3B−H10 angle was mainly conserved among
the 9 systems, particularly within GR LBDAg and GR LBDAnt2
complexes. Conversely, angles H3B−H12 and H10−H12
displayed a more condition-dependent behavior. This was
particularly evident for the GR LBDAnt1 systems, where large
changes were observed in both angles when RU486 was
removed from the LBP or replaced by dex. Although less
pronounced, the GR LBDAnt2 systems also showed certain
differences in the evolution of those angles. Lastly, for GR
LBDAg systems, both angles suffer only narrow deviations, and
solely the imposed presence of RU486 markedly disturbed
angle H3B−H12.
For further characterization of the stabilized H12 con-
formation, we calculated the spatial distribution of the angles
H3B−H12 and H10−H12 over the last 300 ns of the
simulation and plotted them as 2D histograms (Figure 6a).
There, different H12 states achieved by each system are clearly
displayed. In the case of the GR LBDAg, there was a tight
distribution of H3B−H12 and H10−H12 angles, around 75°
and 98°, respectively, corresponding to the GR LBDAg/dex
state. H12 disposition was not perceptibly altered after dex
removal, but its substitution by RU486 slightly withdrew the
receptor from the agonist state. However, the H12 did not turn
toward any of the positions observed for complexes GR
LBDAnt1 or GR LBDAnt2 but in the opposite direction,
interestingly resembling that of the GR LBDAnt3 state (cf.
Figure 3b). This led us to evaluate GR LBDAg/RU486 possible
additional conformational changes. We extended its trajectory
Table 2. Simulated Systems and Average Distances between “Charge Clamp” Residues
distance (Å)a
system receptor ligand Glu755-Lys579 Glu755-Asp590 Asp590-Lys579
1 GR LBDAg Dex 18.4 15.0 11.8
2 GR LBDAg none 18.3 15.0 11.7
3 GR LBDAg RU486 17.8 12.9 11.9
4 GR LBDAnt1 RU486 22.2 21.6 12.0
5 GR LBDAnt1 none 21.5 20.4 11.7
6 GR LBDAnt1 Dex 20.5 20.2 11.9
7 GR LBDAnt2 RU486 20.1 16.6 11.6
8 GR LBDAnt2 none 18.5 15.5 11.4
9 GR LBDAnt2 Dex 18.4 15.2 11.4
aDistance between the Cα of the indicated residues.
Figure 4. Root mean square deviation (RMSD) of the 9 simulated
systems from the initial structures over all backbone atoms (a) or over
H12 backbone atoms (b).
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up to 1000 ns and compared the resulting angle distribution
with GR LBDAg/dex and LBDAg/RU486 300−500 ns (Figure
S4). It was then confirmed that the H12 sustained its drift in
the mentioned direction, partially occupying the AF-2 groove.
This emerging state was termed pseudo-GR LBDAnt3 and
incorporated within our pool of systems.
For the GR LBDAnt1/RU486 complex, histograms showed a
tight angle distribution at 30° for H3B−H12 and 122° for
H10−H12 angles (Figure 6a). By contrast, for the apo and dex
systems, the angle distribution approaches that of GR
LBDAnt2/RU486. Thus, this H12 conformation presumably
describes an intermediate state between the antagonist state
GR LBDAnt1/RU486 and the agonist state GR LBDAg/dex. In
this sense, GR LBDAnt2/apo and GR LBDAnt2/dex histograms
were remarkably similar to that of GR LBDAg/dex and
manifested how the intermediate state evolves toward the
agonist state when RU486 is removed or replaced by dex.
A schematic diagram depicting the evolution of each
simulated system is shown in Figure 6b. The complexes
directly derived from the crystallized structures conserve the
H12 in a position similar to the original one, while variations in
LBP condition modify the H12 destination during the MD.
Figure 7 shows representative snapshots of the main
configurations observed in the H10−H12 and H3B−H12
angle configurational space. It can be observed that while the
C-terminal half of the H12 occupies a similar position in all the
systems, its N-terminal half explores different states swinging
from virtually blocking the AF-2 domain to releasing and
enlarging it.
2.3.3. Dimension of the AF-2 Domain. To estimate how
H12 conformational changes influence the AF-2 configuration,
we calculated the average distance among Cα atoms residues
Glu755 (H12), Lys579 (H3), and Asp590 (H4) (Table 2 and
Figure 8). These residues, localized within each of the AF-2
domain conforming helices, participate in anchoring the
coregulator to the receptor through polar interactions (“charge
clamps”). Hence, the relative position between these three
residues determines the accessibility through the opening
dimension of the AF-2. As expected, the Lys579-Asp590
distance remained equal in all simulated systems, indicating the
permanence in the relative disposition of this coregulator’s
anchor point. In contrast, large variations characterized the
distances involving the H12 residue. Differences of up to 4.4
and 7.5 Å were calculated for the Lys579-Glu755 and Asp590-
Glu755 pairs, respectively, with GR LBDAg/RU486 and GR
LBDAnt1/RU486 at the extremes. These findings evidence that
the AF-2 dimensions and interactions ultimately depend on
H12 spatial configuration.
2.3.4. Ligand Binding Mode. A detailed analysis of the
ligand binding mode was pursued calculating hydrogen bond
interactions between the polar moieties of dex or RU486 and
the polar residues of the GR LBP. Figure S5 displays the
hydrogen-bond occupancy (HBO) between ligand and
receptor atoms for the last 300 ns of the trajectories. Globally,
in the 6 holo-systems these ligand−receptor interactions occur
in well characterized zones, i.e., the C-3 carbonyl group and the
17-hydroxyl group; in addition, dex presents long-lasting
hydrogen bonds through its 11- and 21-hydroxyl groups.
The C-3 carbonyl group of both ligands participates in a
hydrogen bonding network that involves Gln570 (H3) and
Arg611 (H5). In the case of dex, while for the GR LBDAg/dex
and GR LBDAnt1/dex complexes the interaction is mainly
mediated by a water molecule (explaining in part the small
HBO values for the Arg611), larger direct ligand−receptor
contacts are observed for the GR LBDAnt2/dex complex. For
RU486 systems, the agonist state presents similar values for
those interactions, opposite to the nonagonist states which
show little interaction with Gln570 but a more sustained one
with Arg611.
Regarding the 17-hydroxyl group, a persistent hydrogen
bond is formed with Gln642 (H7) in the GR LBDAnt1/dex and,
to some extension, the GR LBDAg/RU486 systems. It is
Figure 5. a) Overall structure of the GR LBDAg/dex complex. Gray tubes display helix-forming residues modeled by Bendix. Segments H3B and
H10 and the H12 helix are marked with black letters. Ligand appears in cyan. b−d) Boxplots of the angles formed between H10−H12 (b), H3B−
H12 (c), and H3B−H10 (d).
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noticeable that the crystal-derived structures only maintain
sporadic interaction with this residue, suggesting that those
contacts within the mentioned complexes are forced due to the
size-occupancy relationship of the LBP and each ligand: a
smaller agonist LBP would shift RU486 orientation toward
Gln642, while a larger LBP conformation would prevent dex
from interacting through its 11- and 21-hydroxyl groups (see
below), thus favoring this bond.
For dex 11- and 21-hydroxyl groups, large HBO values are
detected in the agonist GR LBDAg state, particularly between
the couples 11-hydroxyl/Asn564 (H3) and 21-hydroxyl/
Thr739 (H11). Although less frequently, these are also present
in the GR LBDAnt2/dex complex; on the contrary, as
mentioned before, no interactions between these polar groups
and LBP residues are formed in the antagonist GR LBDAnt1
state. These findings suggest that variations in the H12
position are related with variations in the mode in which 11-
and 21-hydroxyl are recognized by the LBP, plus strengthening
the notion that the GR LBDAnt2 resembles an intermediate
state between GR LBDAg and GR LBDAnt1.
On the other hand, we identified the contact residues for the
RU486 dimethylaniline moiety along each GR LBD/RU486
simulation (Figure S6). In the three systems, this voluminous
group contacts with Gly567 and Gly568 of the H3 and Trp600
localized between the H4 and H5. The third contact point,
however, differs for each complex: Phe749 for GR LBDAg/
RU486, Leu753 for the GR LBDAnt1/RU486, and Ile756 for
the GR LBDAnt2/RU486. Remarkably, the last two belong to
the H12, while the first is located within the H11−H12 loop,
correlating the contacts established by H12 residues with the
RU486 dimethylaniline moiety and the conformation adopted
by the H12.
On the whole, it is noteworthy that all systems bond with at
least one residue of the H3 chain (which has been earlier
proven to be practically invariant), while other interactions are
ultimately related to the GR LBD (and particularly H12)
Figure 6. a) Distribution of the H3B−H12 and H10−H12 angles
population for the simulated systems. Colors indicate relative number
of frames: higher prevalence in red, lower prevalence in yellow. Black
crosses reference the GR LBDAg/dex complex position. b) Schematic
diagram of the H12 evolution along the simulated MD trajectories.
Figure 7. Superposition of the H10−H12/H3B−H12 angle’s
histograms of GR LBDAg/dex, GR LBDAg/RU486 (calculated from
the 500−1000 ns interval), GR LBDAnt1/RU486, and GR LBDAnt2/
RU486 complexes and their corresponding representative snapshots
depicting the different positions adopted by the H12.
Figure 8. AF-2 conformation in the stated systems. Cα atoms of the
receptor residues involved in the “charge clamp” interactions (Lys579,
Asp590, and Glu755) are shown as spheres. The position of the AF-2
groove is indicated with a yellow ellipse.
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configuration. This becomes more evident when ligands are
switched. On the other hand, the number of interactions is
positively correlated with the stability observed in the MDs.
Indeed, systems with larger interactions evidenced less
fluctuations than those with few contacts along their
trajectories, with GR LBDAg/dex representing the most stable
complex.
2.4. Steered Molecular Dynamics Simulation. Through
cMD simulations we have found that the H12 can adopt
numerous positions depending on LBP conditions (i.e., ligand
identity and occupancy), with the GR LBDAg/RU486 (or
pseudo-GR LBDAnt3) at one extreme of the conformational
space and the GR LBDAnt1/RU486 at the other. Considering
the already mentioned limitations of cMD, we alternatively
employed steered MD simulations (SMD) to explore putative
transitions between those two states. In SMD, an external force
is applied to drive the system along a selected reaction
coordinate or “collective variable” (CV) at a constant
velocity.26 The election of an adequate CV capable to describe
the pathway between two states of the protein is mandatory
and usually very challenging.
At first, considering our cMD results, angles H12−H3B and
H12−H11A were taken as CV to displace the H12 in the
absence of ligand, but trajectories proceeded with considerable
deformation in several regions of the receptor. Then, we tested
a combination of distances between Cα atoms of key residues
from H3, H11, and H12, also obtaining inadequate pathways.
Other geometrical descriptors, such as combinations of
distances and angles of the main variable residues, were
equally assessed, with no proper results. Finally, when using
the RMSD of H3, H11, and H12 Cα residues as CV, we
obtained a smooth path between the extreme states without
constitutional deformations and with well conserved secondary
structure elements. Figure 9a shows the temporal evolution of
the CV, and Figure 9b shows the superposition of snapshots
extracted at regular intervals from the 100 ns SMD trajectory.
As it can be observed, along the transition from the pseudo-GR
LBDAnt3 to the GR LBDAnt1, the H12 visits multiple
intermediary conformations, noteworthily including those
corresponding to the GR LBDAg and GR LBDAnt2 original
states.
SMD trajectories were also simulated for dex and RU486
complexes, finding a similar behavior to the apo system, with
straightforward pathways in which both the GR LBD integrity
and secondary structure were conserved. All SMD trajectories
were also analyzed by monitoring the temporal evolution of
the H3B−H12 and H10−H12 angles (Figure S7), finding only
some minor discrepancies among all systems. For example, the
H3B−H12 angle values in the first half of the simulation were
larger in the RU486 complex than in the apo and dex systems,
as was expected due to the bulky substituent of the
antiglucocorticoid. On the other hand, the H10−H12 angle
showed differences between dex and RU486 when the GR
LBDAnt2 state was reached. As a control, SMD trajectories were
also carried out in the reverse direction (from the GR LBDAnt1
to the pseudo-GR LBDAnt3 states) in the three conditions (apo,
dex, and RU486), finding a very similar behavior to that
described in the direct direction (data not shown).
In summary, the one-dimensional path coordinate RMSD
successfully illustrates a complete dynamic picture of the
conformational space sampled by the H12 in the GR LBD.
Hence, this CV was then employed to obtain an energetic
profile of the configurational space.
2.5. Umbrella Sampling Analysis. After validating a
suitable CV for our systems, we performed an Umbrella
Sampling (US) analysis27 using the RMSD of H3, H11, and
H12 Cα atoms as CV. The three SMD trajectories (apo, dex,
and RU486) were sampled every 0.2 Å distance along the CV,
obtaining 25 snapshots for each system. These were then
equilibrated and simulated for 3 ns. The last 2 ns of each
window were integrated with the Umbrella Integration
method.28
The free energy obtained through US was then plotted as a
function of the CV, showing a clear difference between GR
LBD dex and GR LBD RU486 systems (Figure 9c). Indeed, in
the presence of dex, a deep minimum is described at CV = 3.8
Å, which corresponds to the H12 position in the agonistic
conformation (GR LBDAg original state). Large energetically
barriers are observed when the H12 is displaced toward both
GR LBDAnt2 and pseudo-GR LBDAnt3 H12 positions, indicating
that this ligand anchors the H12 in a well-defined and stable
position. This finding sustains the large rigidity observed in the
cMD simulations and explains the full agonistic activity of this
ligand.
In contrast, RU486 provides a flatter free-energy curve, in
accordance with the wider flexibility exhibited by the RU486
systems in cMD simulations. A broad global minimum is
observed at CV = 5 Å, concordant with the pseudo-GR
LBDAnt3 H12 conformation. In turn, GR LBDAnt1 and GR
LBDAnt2 H12 positions do not correlate with any noticeable
minima but to plain regions of the free energy surface. The GR
LBD/apo system also provides a flattened free energy curve
with a slight global minimun at CV = ∼4 Å.
3. CONCLUSION
The GR LBD conform to a compact globular structure whose
end-terminal helices play a crucial role in the activity of this
Figure 9. a) Temporal evolution of the collective variable (RMSD of
Cα atoms of H3, H11, and H12). b) Superposition of 100 SMD
simulation snapshots, sweeping from pseudo-GR LBDAnt3 to GR
LBDAnt1. c) Free energy surface determined by Umbrella Sampling
(GR LBD/dex in red, GR LBD/RU486 in blue, and GR LBD/apo in
black). In all graphics, arrows point to the original GR LBD systems’
position.
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receptor’s domain. Thus, following an approach of con-
catenated MD simulations of different types, we focused on
deciphering the correlation between ligand identity and the GR
LBD H12 dynamic behavior. Even when only two commercial
ligands were evaluated, we consider performing SMD
simulations followed by US analysis a powerful strategy and
a potential tool to satisfactorily understand the molecular basis
of action of glucocorticoids with different activity profiles.
Several GR LBD systems had to be generated starting from
the structure of the nonagonist GR LBD/RU486 complex
(pdb:3h52). This complex crystallized as a tetramer with the
H1 unfolded in the four monomers (resembling the H1
situation described for the native GR LBD apo)25 and required
an in silico refolding in all cases. The straightforward obtention
of stable closed structures upon simulation supports the idea
that the interaction between monomers during the GR LBD/
RU486 crystallization process prevented the H1 from adopting
its complete final shape. Previous studies assessing the ligand’s
access/release to the receptor have mostly spotlighted the
H6−H7 plasticity as an integral part of the ligand-entry
mechanism.29 Our findings, in turn, lead us to consider the GR
LBD/RU486 unfolded H1, far from being a crystallization
artifice, a determinant in ligand association and dissociation
from the GR and a very auspicious element in the
understanding of this process.
A detailed depiction of how two paradigmatic glucocorti-
coids affect the H12 configurational space is also presented.
Moreover, a dynamic GR LBD H12 capable of exploring a
wide range of clearly identified and characterized conforma-
tions is described. Our results reveal pronounced H12
reorientations depending on the LBP conditions, while the
remainder of the GR LBD entails only modest changes in the
N-terminal H3 and the C-terminal H11. Together, these
findings fit within the conformational-selection model in
explaining GR agonism and antagonism.
Potential surface analysis delineated a deep minimum for the
GR LBD dex system, indicating that among all possible
conformations the agonist dex privileges only a few poses,
providing high rigidity to the receptor−ligand complex. As a
consequence, the AF-2 domain remains virtually fixed, suitable
for recognizing coactivators’ LxxLL motifs, as present in
NCoAs. Alternatively, in the presence of the antagonist
RU486, the H12 conformational amplitude appears to be
wider, as indicated by a flatter potential surface energy with no
prominent minimum. Antagonist complexes’ larger flexibility in
comparison to agonist systems has also been described for the
androgen23 and the estrogen receptors.24 Besides, RU486
would also withdraw the H12 from the agonist state and place
it on either side of the ligand’s bulky substituent. From these
observations, we propose that in the absence of coregulators,
the H12 lowest-energy state would be reached when this helix
directly occupies the AF-2 groove. In turn, the presence of
corepressors would stabilize conformations that extend the AF-
2 dimensions. Therefore, H12 conformational selection is a
dynamic equilibrium ultimately determined by both the
identity of the ligand and the presence of corepressors.
Finally, by characterizing novel H12 putative conformations
different from those already crystallized, we provide a whole
series of GR LBD systems that represent potential targets for
the rational design of new glucocorticoid drugs, with the
ultimate aim of finely modulating the GR activity.
4. COMPUTATIONAL METHODS
4.1. Initial GR LBD Structures. Five GR LBD structures
were initially built for the MD simulations (Table 1). The GR
LBDAg coordinates were taken from the crystal structure of the
GR LBD/dex complex (residues 528 to 777 of chain A from
pdb:1m2z). GR LBDAnt1, GR LBDAnt2, and GR LBDAnt3 were
constructed by combining coordinates from two crystal
structures: residues 528 to 554 of chain A of the GR LBD/
dex complex (pdb:1m2z) and residues 555 to 777 of chain A,
B, or C of the crystal structure of the GR LBD/RU486
complex (pdb:3h52). The missing regions in GR LBDAnt2 and
GR LBDAnt3 (Table 1) were modeled with the Modeller
software.30 In all cases, the introduced mutations were reverted
to retrieve the wild-type GR LBD sequence. Using the GR
LBDAg, GR LBDAnt1, and GR LBDAnt2 coordinates, 9 systems
(3 apo and 6 holo) were prepared for classical MD simulations
(Table 2). For the GR LBDAg/dex, GR LBDAnt1/RU486, and
GR LBDAnt2/RU486, the crystal coordinates of the ligands
were conserved. Ligand’s coordinates were directly removed to
obtain apo systems, while for the cross-systems GR LBDAg/
RU486, GR LBDAnt1/dex, and GR LBDAnt2/dex, the HF/6-
31G** optimized structures of the steroids were introduced
into the GR LBD models by superimposing the skeleton
carbon atoms of C and D rings with the corresponding atoms
of the crystallized steroid. For the force field parameters of the
ligands, RESP (restraint electrostatic potential) atomic partial
charges were computed using the HF/6-31G** method in the
quantum chemistry program Gaussian 0931 on the correspond-
ing optimized structures.
4.2. Classical Molecular Dynamics Simulation. Molec-
ular dynamics were performed with the AMBER 18 software
package.32 Ligand parameters were assigned according to the
general AMBER force field (GAFF) and the corresponding
RESP charges using Antechamber. The FF14SB force field
parameters were used for receptor residues. Complexes were
immersed in an octahedral box of TIP3P water molecules
using the Tleap module, giving final systems of about 35,000
atoms. Systems were initially optimized and then gradually
heated up to a final temperature of 300 K. All MD production
runs of 500 ns were performed at 300 K in a NPT ensemble
using periodic boundary conditions and the particle mesh
Ewald method (grid spacing of 1 Å) for treating long-range
electrostatic interactions with a uniform neutralizing plasma.
Temperature regulation was done by using a Langevin
thermostat with a collision frequency of 2 ps−1. The
SHAKE algorithm was used to keep bonds involving H
atoms at their equilibrium length, allowing the use of a 2 fs
time step for the integration of Newton’s equations.
4.3. Steered Molecular Dynamics Simulation. The
RMSD of Cα atoms of H3 (556 to 579), H10−H11 (711 to
740), and H12 (751 to 766) residues was employed as a
collective variable (CV) as it is implemented in the Amber
package.33 The cMD-equilibrated GR LBDAnt1/apo system was
used as a reference (CV = 0 Å) to drive the cMD-equilibrated
pseudo-GR LBDAnt3/apo (CV = 5.1 Å) with a force harmonic
constant of 300 kcal/molÅ2 in a 100 ns long SMD trajectory. A
similar strategy was used to obtain the GR LBD/dex and GR
LBD/RU486 SMD trajectories.
4.4. Umbrella Sampling. Twenty-five snapshots with
equidistant CV 0.2 Å apart were extracted from the SMD
trajectories and prepared for Umbrella Sampling simulations
using parameters as for cMD. Production runs of 3 ns were
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performed as for cMD. Only the last 2 ns were integrated
through the Umbrella Integration method.28
4.5. Analysis of Results. Trajectories were analyzed with
CPPTRAJ,34 and representative snapshots were visualized with
VMD.35 The root mean square fluctuations (RMSF) of Cα
receptor atoms and boxplots were calculated over the last 300
ns of the cMD trajectories. The angle between two α-helices
was computed using a vector for each helix. The vector of an α-
helix was defined by two points determined by the center of
mass of four Cα atoms. Residues 568−571 and 576−579 were
chosen for the starting and ending points of the H3B vector,
residues 712−715 and 718−721 were chosen for the starting
and ending points of the H10 vector, and residues 751−754
and 761−764 were chosen for the starting and ending points of
the H12 vector. Graphical representations of α-helices were
obtained with Bendix.36 Ramachandran plots were obtained
with the RAMPAGE server.37 Hydrogen bond occupancy
(HBO) for each interaction was calculated with the hbond
command of CPPTRAJ using the default parameters for the
distance cutoff (acceptor to donor heavy atom less than 3.0 Å)
and for the angle cutoff (135°).
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